MoonLake CFO Matthias Bodenstedt Sells Shares
Matthias Bodenstedt, CFO of MoonLake Immunotherapeutics, sells 15,082 shares in a planned transaction.
Key Points
- Matthias Bodenstedt, CFO of MoonLake Immunotherapeutics, sold 15,082 shares valued at $296,813.76 on June 17, 2026.
- MoonLake Immunotherapeutics, trading at $19.19, has a market cap of approximately $1.41 billion and a 52-week high of $62.75.
- The company's forward P/E ratio is not meaningful due to negative earnings, with a recommendation key of 'buy' from analysts.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics, sold 15,082 shares of the company on June 17, 2026. The shares were sold at an average price of $19.68, totaling approximately $296,813.76. This transaction was part of a planned sale.
MoonLake Immunotherapeutics Stock Up 49.3%
Shares of NasdaqCM:MLTX traded near $19.19. MoonLake Immunotherapeutics has a market capitalization of about $1.41 billion. The stock has experienced significant fluctuations, with a 52-week low of $5.95 and a high of $62.75. Its 50-day moving average is $17.88, while the 200-day moving average is $19.01. The company's current ratio is 8.60, and its quick ratio is 7.89, indicating strong liquidity. The debt-to-equity ratio stands at 39.68.
$MLTX stock price
Daily closing prices, year to date. Not investment advice.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company based in Zug, Switzerland. It focuses on developing treatments for inflammatory skin and joint diseases. The company's leading product, Sonelokimab, is a novel therapy targeting IL-17A and IL-17F for conditions such as hidradenitis suppurativa, psoriatic arthritis, and psoriasis. Founded in 2021, MoonLake is led by CEO Dr. Jorge Santos da Silva and employs around 130 people.
Bottom Line
This insider sale by MoonLake's CFO, Matthias Bodenstedt, is part of a planned transaction. Investors often watch insider transactions for signals about company prospects, but it's important to note that such sales can occur for many reasons unrelated to the business outlook. MoonLake's stock has shown volatility, and while the forward P/E ratio isn’t meaningful due to current losses, analysts maintain a 'buy' recommendation.
Get MoonLake Immunotherapeutics alerts
New 13F filings, insider trades, and analyst moves on $MLTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.